Tocilizumab in the treatment of active chronic humoral rejection resistant to standard therapy
Introduction: There is no consensus on the most appropriate treatment for chronic active antibody-mediated rejection (cAMR). Recent studies suggest that treatment with tocilizumab (TCZ) may stabilize graft function, decrease the intensity of donor-specific HLA antibodies (DSAs) and reduce inflammati...
| Hlavní autoři: | , , , , , , , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
Elsevier
2022-09-01
|
| Edice: | Nefrología (English Edition) |
| Témata: | |
| On-line přístup: | http://www.sciencedirect.com/science/article/pii/S2013251423000147 |